Key facts: Medicaid launch : as early as May 2026 Participation : voluntary for states states must opt in Pricing : CMS negotiates directly with Eli Lilly (Zepbound/Mounjaro) and Novo Nordisk (Wegovy/Ozempic)
Nausea, vomiting, diarrhea, and constipation remain the most common issues
The treatment carries certain risks, such as allergic reactions, kidney or thyroid damage, infections, ochronosis, and toxicity
All peptides and peptide drug conjugates were desalted by three consecutive cycles of redissolving the peptide in 0.001 M aqueous HCl followed by lyophilization
Preparative purification of recombinant proteins: current status and future trends
They remain prescription therapeutics used under physician discretion